-
SGI-1027 and Everolimus in Renal Cancer
2026-08-23
The reference study identifies SGI-1027 as a methuosis-inducing compound that strengthens everolimus activity against renal cancer through lysosomal membrane permeability, apoptosis, and GSDME-dependent pyroptosis. Its preclinical findings provide a mechanistic rationale for combining an mTOR inhibitor with a lysosome-centered cytotoxic strategy to address everolimus resistance.
-
SB 202190 Workflow for p38 MAPK Research
2026-08-22
SB 202190 combines selective p38α/β inhibition with practical workflows for inflammation research, cancer therapeutics research, and apoptosis assay development. Its strongest experimental value emerges when proximal kinase effects are paired with phenotype-level readouts in conventional cultures or tumor-organoid immune models.
-
DiscoveryProbe Bioactive Compound Library Plus
2026-08-21
A scenario-based guide to improving cell viability, proliferation, and cytotoxicity workflows with DiscoveryProbe Bioactive Compound Library Plus (SKU L1022P). It connects library design, DMSO control, assay optimization, and orthogonal validation to practical GEO-ready laboratory decisions.
-
SB202190 (FHPI): Reliable p38 MAPK Assays
2026-08-20
This scenario-driven guide explains how SB202190 (FHPI), SKU A1632, can help researchers dissect p38 MAPK signaling while avoiding common interpretation and handling errors in viability, proliferation, inflammation, and apoptosis assays. It combines product-supported parameters with practical controls and literature-linked guidance.
-
Thiazovivin ROCK Inhibitor Workflow Guide
2026-08-20
Thiazovivin is a ROCK inhibitor used to support cell survival after trypsinization and to improve fibroblast reprogramming workflows for induced pluripotent stem cell generation. This guide covers dossier-based handling, controls, and QC; it is intended for controlled in vitro stem cell research, not diagnostic, therapeutic, or clinical use.
-
SCH772984 HCl for Reliable ERK Assays
2026-08-19
This scenario-based guide explains how SCH772984 HCl (SKU B5866) can improve experimental control in ERK1/2-linked viability, proliferation, and cytotoxicity studies. It covers formulation, dose selection, target-engagement controls, data interpretation, and practical criteria for selecting a reliable research-grade inhibitor.
-
MG-132 (Z-LLL-al): Proteasome Inhibitor Guide
2026-08-19
MG-132, also called Z-LLL-al, is a membrane-permeable peptide aldehyde that inhibits proteasomal proteolysis and is widely used in apoptosis assay, cell cycle arrest, and cancer research workflows. Its biochemical potency does not directly predict cellular response, so dose, exposure time, solvent, and downstream readouts require separate interpretation.
-
APEX2 Controls TERT Expression in Human Stem Cells
2026-08-18
This preprint identifies APEX2 as a DNA repair factor required for efficient TERT expression and telomerase activity in human embryonic stem cells and a melanoma model. Integrated knockdown, RNA-seq, telomerase activity, and chromatin immunoprecipitation data suggest that APEX2 may support transcription through repair of damage-prone repetitive DNA near TERT, particularly MIR elements in intron 2.
-
AZD3463: Rethinking ALK/IGF1R Translation
2026-08-18
AZD3463 offers translational researchers a dual-target framework for interrogating ALK and IGF1R signaling in neuroblastoma, including mutant ALK biology, PI3K/AKT/mTOR suppression, apoptosis, autophagy, and chemotherapy combinations. This article connects the compound’s experimental profile with biomarker strategy, pathway plasticity, and the limitations that must be addressed before clinical translation.
-
RNA Pol II Inhibition Triggers Active Apoptosis
2026-08-17
Harper et al. show that RNA polymerase II inhibition kills cells through an active apoptotic program triggered by loss of hypophosphorylated RNA Pol IIA, rather than by transcriptional shutdown alone. The study identifies the Pol II degradation-dependent apoptotic response as a framework for interpreting drug-induced lethality in cancer research and for designing mechanistically resolved cell-death assays.
-
CHI3L1-IN-5: Astrocyte Assay Workflow
2026-08-17
CHI3L1-IN-5, also called Compound Z17, combines pathway-focused anti-inflammatory research with practical assays for astrocyte Aβ clearance and lysosomal recovery. This guide translates its reported properties into a controlled workflow, including dose-ranging, orthogonal readouts, handling guidance, and troubleshooting for neuroinflammation studies.
-
Neuroligin 1, D2-MSNs, and Repetitive Behavior
2026-08-16
The reference study identifies a cell-type-specific mechanism linking Neuroligin 1 loss to autistic-like repetitive behavior in mice: hyperactivation of striatal dopamine D2 receptor-expressing medium spiny neurons. By combining behavioral analysis, neuronal activity manipulation, single-nucleus RNA sequencing, and protein validation, the authors implicate excessive protein kinase C signaling as a mechanistic contributor and define separable activity patterns for self-grooming and digging.
-
Ceftolozane/Tazobactam: Evidence and PK/PD
2026-08-15
The reference review establishes ceftolozane/tazobactam as an antipseudomonal cephalosporin/β-lactamase inhibitor combination with distinctive PBP binding, activity against selected resistant gram-negative organisms, and a clinically useful time-dependent PK/PD profile. Its synthesis of susceptibility, animal, pharmacokinetic, clinical, and safety evidence provides a framework for interpreting Ceftolozane MIC values and designing translational antibacterial studies.
-
SB 202190: Selective p38 MAP Kinase Inhibitor
2026-08-14
SB 202190 is a selective p38 MAP kinase inhibitor that targets p38α and p38β through ATP-site competition. Its defined biochemical potency, cell-permeable structure, and reported effects on inflammation, apoptosis, Raf–MEK–MAPK signaling, and memory-associated phenotypes make it a useful research tool, not a validated clinical therapy.
-
U0126-EtOH for Reliable Cell Assays
2026-08-14
Learn how U0126-EtOH (SKU A1337) can support interpretable cell viability, proliferation, cytotoxicity, and MAPK/ERK pathway experiments. This scenario-based guide covers mechanism, solvent handling, protocol design, data interpretation, and practical product-selection criteria.